Answer from: Radiation Oncologist at Community Practice
I offer all three (APBI, FAST, FAST-Forward) based on eligibility and let the patient decide.
Comments
Radiation Oncologist at Mon Health Based on the UK 10-year data, are there late toxic...
Radiation Oncologist at Lake Huron Medical Center What's the benefit of the once-a-week approach? Lo...
Radiation Oncologist at University of Texas Health Science Center San Antonio MD Anderson Mays Cancer Center Exactly. Some patients drive from multiple hours a...
Radiation Oncologist at Vanderbilt-Ingram Cancer Center 26 Gy in 1 week has a similar outcome as 28.5 Gy W...
Radiation Oncologist at University of Texas Health Science Center San Antonio MD Anderson Mays Cancer Center Agree with your comments about dose. 30 Gy in 5 AP...
Answer from: Radiation Oncologist at Academic Institution
While I don't make these schedules my primary recommendation, there are patients for whom the logistics make a big difference. In those cases, I will offer these regimens in low-risk disease without adverse features (like things I'd normally boost) and "normal" anatomy. I keep in mind the follow-up ...
Answer from: Radiation Oncologist at Community Practice
As per the UK guidelines, and drawing on IMPORT-LOW and FAST-Forward, don't you think 26 Gy in 5 fr daily PBI is reasonable (and more compelling) as well for most PBI-eligible patients? In the FLORENCE trial, 30 Gy in 5f EOD was compared to 50 Gy plus boost 10 Gy, and only ~50% of the patients met t...
Answer from: Radiation Oncologist at Community Practice
APBI is an excellent option for eligible patients. If they are not eligible for APBI by criteria, but they would qualify for FAST/FAST-Forward, I always prefer the FAST-Forward regimen, especially for patients coming from a distance.
Answer from: Radiation Oncologist at Community Practice
Based on patient preference: either APBI, FAST, or FAST-Forward. Based on personal preference: FAST (while using FAST-Forward constraints). Based on eligibility criteria on trials: the FAST eligibility (≥ 50 yo, pT1-2 pN0) more accurately represents the patient population at my clinic r...
Answer from: Radiation Oncologist at Community Practice
The trouble for me is that not all the research is pointing in the same direction. With some trials demonstrating worse cosmesis and slightly higher IBTR or nodal failures with APBI and no serious downside to treating the whole breast, until we have better evidence, it makes sense to me to continue ...